Assessing the Internationalization Capabilities of Life Science New Ventures

Jones, Martin; Wheeler, Colin; Dimitratos, Pavlos; Vlachos, G.

doi:10.4337/9781849808200.00008

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osiris, Genentec) have organized clinical stem cell trials in the US, and to a lesser extent in other countries, companies and researchers look to the state and NPOs for financial support (Dutton, 2007; Littman, 2014). The shortage of investment in RM means there is a great number of small biotech start-ups in academia that need to become self-sufficient, which has led to extensive licensing and to the globalization of this trade – not so much in health products, but in products or services for conducting research (Jones et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine

Sleeboom-Faulkner

2019

Soc Stud Sci

View full text Add to dashboard Cite

This article concerns the roles of entrepreneurial scientists in the co-production of life science research and regulation. Regulatory brokerage, defined as a mode of strategic planning and as the negotiation of regulation based on comparative advantage and competition, is expressed in scientific activities that take advantage of regulatory difference. This article is based on social science research in Japan, Thailand, India and the UK. Using five cases related to Japan’s international activities in the field of regenerative medicine, I argue that, driven by competitive advantage, regulatory brokerage at lower levels of managerial organization and governance is emulated at higher levels. In addition, as regulatory brokerage affects the creation of regulation at national, bilateral and global levels, new regulation may be based on competition in regulatory advantage rather than on ethical and scientific values. I argue that regulatory brokerage as the basis for regulatory reform bypasses issues that need to be decided by a broader public. More space is needed for international and political debate about the socio-political consequences of the global diversity of regulation in the field of the life sciences.

show abstract

Section: Introductionmentioning

confidence: 99%

Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine

Sleeboom-Faulkner

2019

Soc Stud Sci

View full text Add to dashboard Cite

show abstract

Assessing the Internationalization Capabilities of Life Science New Ventures

Cited by 1 publication

References 0 publications

Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine

Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine

Contact Info

Product

Resources

About